MTOR and neoplasm: Carver et al. (2011) reported that the use of the dual PI3K/mTOR inhibitor BEZ235 (also known as Dactolisib) and of enzultamide induces cell death in a Pten-deficient PCa mouse model, which results in ∼80% of tumor regression (Carver et al., 2011).